AIM: To explore the prevalence of autoimmune gastritis in chronic hepatitis C virus (HCV) patients and the influence of alpha-interferon (IFN) treatment on autoimmune gastritis. METHODS: We performed a prospective study on 189 patients with positive anti-HCV and viral RNA enrolled in a 12-month IFN protocol. We evaluated: a) the baseline prevalence of autoimmune gastritis, b) the impact of IFN treatment on development of biochemical signs of autoimmune gastritis (at 3, 6 and 12 months), c) the evolution after IFN withdrawal (12 months) in terms of anti-gastric-parietal-cell antibodies (APCA), gastrin, anti-thyroid, and anti-non-organ-specific antibodies. RESULTS: APCA positivity and 3-fold gastrin levels were detected in 3 (1.6 %) and 9 (5 %) patients, respectively, at baseline, in 25 (13 %) and 31 (16 %) patients at the end of treatment (both P<0.001, vs baseline), and in 7 (4 %) and 14 (7 %) patients 12 months after withdrawal (P=0.002 and P=0.01 respectively, vs baseline; P=not significant vs end of treatment). The development of autoimmune gastritis was strictly associated with the presence of autoimmune thyroiditis (P =0.0001), no relationship was found with other markers of autoimmunity. CONCLUSION: In HCV patients, IFN frequently precipitates latent autoimmune gastritis, particularly in females. Following our 12-month protocol, the phenomenon generally regressed. Since APCA positivity and high gastrin levels are associated with the presence of antithyroid antibodies, development of autoimmune thyroiditis during IFN treatment may provide a surrogate preliminary indicator of possible autoimmune gastritis to limit the need for invasive examinations.
AIM: To explore the prevalence of autoimmune gastritis in chronic hepatitis C virus (HCV) patients and the influence of alpha-interferon (IFN) treatment on autoimmune gastritis. METHODS: We performed a prospective study on 189 patients with positive anti-HCV and viral RNA enrolled in a 12-month IFN protocol. We evaluated: a) the baseline prevalence of autoimmune gastritis, b) the impact of IFN treatment on development of biochemical signs of autoimmune gastritis (at 3, 6 and 12 months), c) the evolution after IFN withdrawal (12 months) in terms of anti-gastric-parietal-cell antibodies (APCA), gastrin, anti-thyroid, and anti-non-organ-specific antibodies. RESULTS: APCA positivity and 3-fold gastrin levels were detected in 3 (1.6 %) and 9 (5 %) patients, respectively, at baseline, in 25 (13 %) and 31 (16 %) patients at the end of treatment (both P<0.001, vs baseline), and in 7 (4 %) and 14 (7 %) patients 12 months after withdrawal (P=0.002 and P=0.01 respectively, vs baseline; P=not significant vs end of treatment). The development of autoimmune gastritis was strictly associated with the presence of autoimmune thyroiditis (P =0.0001), no relationship was found with other markers of autoimmunity. CONCLUSION: In HCVpatients, IFN frequently precipitates latent autoimmune gastritis, particularly in females. Following our 12-month protocol, the phenomenon generally regressed. Since APCA positivity and high gastrin levels are associated with the presence of antithyroid antibodies, development of autoimmune thyroiditis during IFN treatment may provide a surrogate preliminary indicator of possible autoimmune gastritis to limit the need for invasive examinations.
Authors: M Renga; G Brandi; G M Paganelli; C Calabrese; S Papa; A Tosti; P Tomassetti; M Miglioli; G Biasco Journal: Gut Date: 1997-09 Impact factor: 23.059
Authors: N Ganne-Carrie; A Medini; E Coderc; O Seror; C Christidis; S Grimbert; J C Trinchet; M Beaugrand Journal: J Autoimmun Date: 2000-03 Impact factor: 7.094
Authors: K H Meyer zum Büschenfelde; A W Lohse; G Gerken; U Treichel; H F Löhr; H Mohr; A Grosse; H P Dienes Journal: J Hepatol Date: 1995 Impact factor: 25.083
Authors: Y Nagayama; K Ohta; M Tsuruta; A Takeshita; H Kimura; K Hamasaki; K Ashizawa; K Nakata; N Yokoyama; S Nagataki Journal: Endocr J Date: 1994-10 Impact factor: 2.349
Authors: G Mazzella; A Salzetta; S Casanova; M C Morelli; N Villanova; R Miniero; S Sottili; V Novelli; A Cipolla; D Festi Journal: Dig Dis Sci Date: 1994-04 Impact factor: 3.199
Authors: Laura M Stinton; Chelsea Bentow; Michael Mahler; Gary L Norman; Bertus Eksteen; Andrew L Mason; Gilaad G Kaplan; Bjorn Lindkvist; Gideon M Hirschfield; Piotr Milkiewicz; Angela Cheung; Harry L A Janssen; Marvin J Fritzler Journal: PLoS One Date: 2014-11-14 Impact factor: 3.240
Authors: S John Calise; Nicola Bizzaro; Thuy Nguyen; Danila Bassetti; Brunetta Porcelli; Paolo Almi; Giuseppina Barberio; Giampaola Pesce; Minoru Satoh; Edward K L Chan Journal: Auto Immun Highlights Date: 2016-11-14